August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone
Physical therapy addressing core stability, posture correction, and spinal mobility can be highly effective before considering medication changes
Prescription weight-loss treatment may be appropriate for adults who: Have a BMI 30 Have a BMI 27 with obesity-related health problems Have struggled to reduce body weight despite structured lifestyle changes Have metabolic or cardiometabolic risk factor A comprehensive initial consultation is required before any prescription is issued
Stephen Cunnanes work describes the role of brain energy rescue in combating neurodegenerative diseases, including dementia, and Alzheimers disease [9]
Once a week, the nurse came to my house to clean the line and draw my blood, so my doctor could run lab work to make sure I was reacting well to the medication
